Trump Administration Initiates Kidney Care National Plan

The Trump administration recently launched the Kidney Care National Plan, aiming to enhance structural kidney care and address deficiencies that result in heightened costs and diminished care quality, as stated by the Health and Human Services (HHS) Department.

The new plan seeks to introduce more competition in treatment markets, which have historically been dominated by DaVita Inc. and Fresenius Medical Care, controlling approximately 74% of the market. A reform of the transplant system is a central focus of the initiative.

With approximately 90,000 Americans on the kidney transplant waiting list, often experiencing delays of three to five years, the HHS intends to advance a National Transplant Expansion Strategy. This strategy builds upon a foundation established by a 2019 executive order during President Trump’s tenure, making living donation more accessible for patients requiring transplants.

The plan prioritizes preventive care by aiming for early detection of kidney disease, earlier interventions, and progression-inhibiting treatments. Affecting an estimated 37 million American adults, kidney disease ranks among the most common chronic illnesses in the nation. Many of those affected remain unaware of their condition, leading to delayed treatment after significant damage has occurred.

“In many cases, government should do less, focusing its efforts on promoting accountability, competition, and innovation,” the plan recommends.

HHS points to systemic failures, partially attributing them to government overreach. A major obstacle to improved prevention emerges from the federal government’s responsibility for financing end-stage renal disease care. The plan suggests the government should limit its role to specific situations where market failures hinder private entities from effectively serving the public interest.